India's Trusted Partner for
Named Patient Medicines.
We enable seamless access to critical and hard-to-find medicines through structured Named Patient Programs, ensuring safe, compliant, and timely delivery for patients in India.
Bridging Access Through
Named Patient Program
The Named Patient Program (NPP), also known as a Managed Access Program, provides patients in India access to medicines approved in other countries but not yet locally available, ensuring safe, timely, and compliant delivery of essential therapies.
From Search & Approval
to Global Medicine Access
When access goes beyond borders, this is the path your medicine follows.
Search & Request
The patient or doctor searches for the medicine and submits a request.
Verification & Review
Our team carefully verifies availability and eligibility.
Quote & Timeline
Transparent quotation and delivery timelines are shared upfront.
Approval Pathway
Necessary approvals are secured to enable safe access.
Temperature-Controlled Import
Medicines are imported under the highest standards for safe, temperature-controlled transport.
Doorstep Delivery
Medicines are securely delivered to the patient's doorstep.
Medicines by Therapeutic
Category
Supporting patients and doctors in finding the right therapies.
.webp)
Request medicine with Valid Prescription
A trusted process designed to help patients access essential prescribed medicines securely across borders.
India's Leading Platform for
Named Patient Medicine Access
Providing structured product categories with safe, compliant, and reliable global access.
Is it legal in India
to import?
In India, the import of medicines for personal use is permitted under the Drugs and Cosmetics Act, 1940, subject to specific conditions. As per Rule 36 of the Drugs and Cosmetics Rules, individuals may import limited quantities of prescribed medicines for personal use, supported by a valid prescription and necessary regulatory approvals. This process helps ensure that imported medicines meet safety, quality, and regulatory standards.
Trusted Expertise in Global
Medicine Access and Support
Providing compliant access, reliable logistics, and dedicated support for patient needs
10+
Years of Expertise
15,000+
Patients Served
1.5 Million+
Product Lines
24/7
Temperature Monitoring
2+
EU-GDP Certified Warehouses
Latest News and Updates
Stay informed with our recent developments, insights, and announcements
Moderna’s 2025–2026 COVID-19 Vaccines Receive FDA Approval
The 2025–2026 formulations of Moderna’s COVID-19 vaccines, Spikevax® and mNexspike®, have received approval from the U.S. Food and Drug Administration (FDA). The LP.8.1 strain of SARS-CoV-2, which was suggested by the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) at its May 2025 meeting, is the target of these updated vaccines.
Read moreFDA Approves First Intranasal Diuretic, Enbumyst
Enbumyst (bumetanide nasal spray), developed by Corstasis Therapeutics, has received approval from the U.S. Food and Drug Administration (FDA). It is the first intranasal diuretic approved for the treatment of edema associated with congestive heart failure, hepatic disease, and renal disease, including nephrotic syndrome, in adults.
Read moreGet in touch
Reach out, and let's create a universe of possibilities together!
Let's us help!
We get back to you shortly during our working hours.
Discuss Your
Problem
Trusted support you can rely on.
Mail Us At:
info@namedpatientprogram.com
Contact Us:
+91 9810469557
Latest News and Updates
Stay informed with our recent developments, insights, and announcements
Moderna’s 2025–2026 COVID-19 Vaccines Receive FDA Approval
The 2025–2026 formulations of Moderna’s COVID-19 vaccines, Spikevax® and mNexspike®, have received approval from the U.S. Food and Drug Administration (FDA). The LP.8.1 strain of SARS-CoV-2, which was suggested by the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) at its May 2025 meeting, is the target of these updated vaccines.
Read moreFDA Approves First Intranasal Diuretic, Enbumyst
Enbumyst (bumetanide nasal spray), developed by Corstasis Therapeutics, has received approval from the U.S. Food and Drug Administration (FDA). It is the first intranasal diuretic approved for the treatment of edema associated with congestive heart failure, hepatic disease, and renal disease, including nephrotic syndrome, in adults.
Read more